title: Relationship between serum potassium concentration and risk of recurrent ventricular tachycardia or ventricular fibrillation.
abstract: BACKGROUND
  Electrolyte abnormalities are considered a correctable cause of a life-threatening ventricular arrhythmia according to American Heart Association/American College of Cardiology Practice Guidelines, and ventricular tachycardia or ventricular fibrillation in the setting of an electrolyte abnormality is considered a class III indication for defibrillator implantation. However, there are little data to support this recommendation. The purpose of this study was to determine the risk of a recurrent sustained ventricular arrhythmia in patients with a low serum potassium concentration at the time of an initial episode of a sustained ventricular arrhythmia.
  
  
  RESULTS
  One hundred sixty-nine consecutive patients who presented with a sustained ventricular arrhythmia and a serum potassium concentration determined on the day of the arrhythmia underwent defibrillator implantation. All patients had structural heart disease and left ventricular ejection fraction of 0.32+/-0.15. On the day of the index arrhythmia, 30% of the patients had a serum potassium concentration <3.5 or >5.0 mEq/L, including 7% who had a serum potassium concentration <3.0 or >6.0 mEq/L. For the entire cohort of patients, freedom from a recurrent sustained ventricular arrhythmia was 18% at 5 years and was not significantly different among patients with a serum potassium concentration <3.5 mEq/L (23%), between 3.5 and 5.0 mEq/L (16%), and >5.0 mEq/L (5%; P = 0.1).
  
  
  CONCLUSIONS
  The results of the present study suggest that patients with structural heart disease and an abnormal serum potassium concentration at the time of an initial episode of sustained ventricular tachycardia or ventricular fibrillation are at high risk for a recurrent ventricular arrhythmia; therefore, implantable defibrillator therapy may be reasonable.
authors.affiliation: Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor 48109-0022, USA.
authors.forename: G F
authors.initials: GF
authors.lastname: Michaud
authors.forename: C
authors.initials: C
authors.lastname: Sticherling
authors.forename: H
authors.initials: H
authors.lastname: Tada
authors.forename: H
authors.initials: H
authors.lastname: Oral
authors.forename: F
authors.initials: F
authors.lastname: Pelosi
authors.forename: B P
authors.initials: BP
authors.lastname: Knight
authors.forename: F
authors.initials: F
authors.lastname: Morady
authors.forename: S A
authors.initials: SA
authors.lastname: Strickberger
mesh_terms: D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008824:Michigan / Q000453:epidemiology; D008875:Middle Aged; D011188:Potassium / Q000097:blood*; D017410:Practice Guidelines as Topic; D011237:Predictive Value of Tests; D012008:Recurrence; D012307:Risk Factors; D017180:Tachycardia, Ventricular / Q000097:blood* / Q000453:epidemiology*; D014693:Ventricular Fibrillation / Q000097:blood* / Q000453:epidemiology*
chemical_list: D011188:Potassium